Does gabexate mesilate affect serum concentrations of acute phase proteins after endoscopic retrograde cholangiopancreatography examination?

Raffaele Pezzilli, Armando Gabbrielli, Antonio Maria Morselli Labate, Pasquale D'Alessio, Bahjat Barakat, Guido Costamagna, Francesco Dibenedetti, Margherita Massa, Giovanni Merlini, Gianvico Melzi D'Eril

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background/Aims: To explore the possibility that the preventive effect of gabexate mesilate on endoscopic retrograde cholangiopancreatography-related acute pancreatitis may be mediated by its modulation of acute phase proteins. Methodology: Thirty consecutive patients who underwent endoscopic retrograde cholangiopancreatography were randomly assigned to receive 1g of gabexate mesilate (13 patients) or a placebo (17 patients) by continuous i.v. infusion starting 30 minutes before the endoscopy session and continuing for 12 hours afterward. In all patients, C-reactive protein, serum amyloid A and interleukin 6 serum concentrations were determined before endoscopy and 4, 8, 12 and 24 hours afterward. Results: Interleukin 6 basal serum concentrations were not statistically different between patients who had been treated with gabexate mesilate and those who had received the placebo (P=0.279), whereas C-reactive protein (P=0.033) and serum amyloid A (P=0.022) basal values were significantly lower in the gabexate mesilate group than in the placebo group. Compared to basal values, serum interleukin 6 concentrations significantly increased at 4 (P=0.048) and at 8 (P=0.025) hours; the increase of serum interleukin 6 concentrations was not significant at 12 (P=0.092), but became significant at 24 (P=0.025) hours. C-reactive protein and serum amyloid A serum concentrations increased significantly only at 12 (P=0.001, P=0.012, respectively) and 24 (P

Original languageEnglish
Pages (from-to)851-855
Number of pages5
JournalHepato-Gastroenterology
Volume50
Issue number51
Publication statusPublished - May 2003

Fingerprint

Gabexate
Acute-Phase Proteins
Endoscopic Retrograde Cholangiopancreatography
Serum Amyloid A Protein
Interleukin-6
C-Reactive Protein
Serum
Placebos
Endoscopy
Pancreatitis

Keywords

  • Acute Phase Proteins
  • Clinical Study
  • ERCP
  • Gabexate
  • Pancreatitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Pezzilli, R., Gabbrielli, A., Morselli Labate, A. M., D'Alessio, P., Barakat, B., Costamagna, G., ... Melzi D'Eril, G. (2003). Does gabexate mesilate affect serum concentrations of acute phase proteins after endoscopic retrograde cholangiopancreatography examination? Hepato-Gastroenterology, 50(51), 851-855.

Does gabexate mesilate affect serum concentrations of acute phase proteins after endoscopic retrograde cholangiopancreatography examination? / Pezzilli, Raffaele; Gabbrielli, Armando; Morselli Labate, Antonio Maria; D'Alessio, Pasquale; Barakat, Bahjat; Costamagna, Guido; Dibenedetti, Francesco; Massa, Margherita; Merlini, Giovanni; Melzi D'Eril, Gianvico.

In: Hepato-Gastroenterology, Vol. 50, No. 51, 05.2003, p. 851-855.

Research output: Contribution to journalArticle

Pezzilli, R, Gabbrielli, A, Morselli Labate, AM, D'Alessio, P, Barakat, B, Costamagna, G, Dibenedetti, F, Massa, M, Merlini, G & Melzi D'Eril, G 2003, 'Does gabexate mesilate affect serum concentrations of acute phase proteins after endoscopic retrograde cholangiopancreatography examination?', Hepato-Gastroenterology, vol. 50, no. 51, pp. 851-855.
Pezzilli R, Gabbrielli A, Morselli Labate AM, D'Alessio P, Barakat B, Costamagna G et al. Does gabexate mesilate affect serum concentrations of acute phase proteins after endoscopic retrograde cholangiopancreatography examination? Hepato-Gastroenterology. 2003 May;50(51):851-855.
Pezzilli, Raffaele ; Gabbrielli, Armando ; Morselli Labate, Antonio Maria ; D'Alessio, Pasquale ; Barakat, Bahjat ; Costamagna, Guido ; Dibenedetti, Francesco ; Massa, Margherita ; Merlini, Giovanni ; Melzi D'Eril, Gianvico. / Does gabexate mesilate affect serum concentrations of acute phase proteins after endoscopic retrograde cholangiopancreatography examination?. In: Hepato-Gastroenterology. 2003 ; Vol. 50, No. 51. pp. 851-855.
@article{b9c8713cbee8432bad0ec3136b7877c1,
title = "Does gabexate mesilate affect serum concentrations of acute phase proteins after endoscopic retrograde cholangiopancreatography examination?",
abstract = "Background/Aims: To explore the possibility that the preventive effect of gabexate mesilate on endoscopic retrograde cholangiopancreatography-related acute pancreatitis may be mediated by its modulation of acute phase proteins. Methodology: Thirty consecutive patients who underwent endoscopic retrograde cholangiopancreatography were randomly assigned to receive 1g of gabexate mesilate (13 patients) or a placebo (17 patients) by continuous i.v. infusion starting 30 minutes before the endoscopy session and continuing for 12 hours afterward. In all patients, C-reactive protein, serum amyloid A and interleukin 6 serum concentrations were determined before endoscopy and 4, 8, 12 and 24 hours afterward. Results: Interleukin 6 basal serum concentrations were not statistically different between patients who had been treated with gabexate mesilate and those who had received the placebo (P=0.279), whereas C-reactive protein (P=0.033) and serum amyloid A (P=0.022) basal values were significantly lower in the gabexate mesilate group than in the placebo group. Compared to basal values, serum interleukin 6 concentrations significantly increased at 4 (P=0.048) and at 8 (P=0.025) hours; the increase of serum interleukin 6 concentrations was not significant at 12 (P=0.092), but became significant at 24 (P=0.025) hours. C-reactive protein and serum amyloid A serum concentrations increased significantly only at 12 (P=0.001, P=0.012, respectively) and 24 (P",
keywords = "Acute Phase Proteins, Clinical Study, ERCP, Gabexate, Pancreatitis",
author = "Raffaele Pezzilli and Armando Gabbrielli and {Morselli Labate}, {Antonio Maria} and Pasquale D'Alessio and Bahjat Barakat and Guido Costamagna and Francesco Dibenedetti and Margherita Massa and Giovanni Merlini and {Melzi D'Eril}, Gianvico",
year = "2003",
month = "5",
language = "English",
volume = "50",
pages = "851--855",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "51",

}

TY - JOUR

T1 - Does gabexate mesilate affect serum concentrations of acute phase proteins after endoscopic retrograde cholangiopancreatography examination?

AU - Pezzilli, Raffaele

AU - Gabbrielli, Armando

AU - Morselli Labate, Antonio Maria

AU - D'Alessio, Pasquale

AU - Barakat, Bahjat

AU - Costamagna, Guido

AU - Dibenedetti, Francesco

AU - Massa, Margherita

AU - Merlini, Giovanni

AU - Melzi D'Eril, Gianvico

PY - 2003/5

Y1 - 2003/5

N2 - Background/Aims: To explore the possibility that the preventive effect of gabexate mesilate on endoscopic retrograde cholangiopancreatography-related acute pancreatitis may be mediated by its modulation of acute phase proteins. Methodology: Thirty consecutive patients who underwent endoscopic retrograde cholangiopancreatography were randomly assigned to receive 1g of gabexate mesilate (13 patients) or a placebo (17 patients) by continuous i.v. infusion starting 30 minutes before the endoscopy session and continuing for 12 hours afterward. In all patients, C-reactive protein, serum amyloid A and interleukin 6 serum concentrations were determined before endoscopy and 4, 8, 12 and 24 hours afterward. Results: Interleukin 6 basal serum concentrations were not statistically different between patients who had been treated with gabexate mesilate and those who had received the placebo (P=0.279), whereas C-reactive protein (P=0.033) and serum amyloid A (P=0.022) basal values were significantly lower in the gabexate mesilate group than in the placebo group. Compared to basal values, serum interleukin 6 concentrations significantly increased at 4 (P=0.048) and at 8 (P=0.025) hours; the increase of serum interleukin 6 concentrations was not significant at 12 (P=0.092), but became significant at 24 (P=0.025) hours. C-reactive protein and serum amyloid A serum concentrations increased significantly only at 12 (P=0.001, P=0.012, respectively) and 24 (P

AB - Background/Aims: To explore the possibility that the preventive effect of gabexate mesilate on endoscopic retrograde cholangiopancreatography-related acute pancreatitis may be mediated by its modulation of acute phase proteins. Methodology: Thirty consecutive patients who underwent endoscopic retrograde cholangiopancreatography were randomly assigned to receive 1g of gabexate mesilate (13 patients) or a placebo (17 patients) by continuous i.v. infusion starting 30 minutes before the endoscopy session and continuing for 12 hours afterward. In all patients, C-reactive protein, serum amyloid A and interleukin 6 serum concentrations were determined before endoscopy and 4, 8, 12 and 24 hours afterward. Results: Interleukin 6 basal serum concentrations were not statistically different between patients who had been treated with gabexate mesilate and those who had received the placebo (P=0.279), whereas C-reactive protein (P=0.033) and serum amyloid A (P=0.022) basal values were significantly lower in the gabexate mesilate group than in the placebo group. Compared to basal values, serum interleukin 6 concentrations significantly increased at 4 (P=0.048) and at 8 (P=0.025) hours; the increase of serum interleukin 6 concentrations was not significant at 12 (P=0.092), but became significant at 24 (P=0.025) hours. C-reactive protein and serum amyloid A serum concentrations increased significantly only at 12 (P=0.001, P=0.012, respectively) and 24 (P

KW - Acute Phase Proteins

KW - Clinical Study

KW - ERCP

KW - Gabexate

KW - Pancreatitis

UR - http://www.scopus.com/inward/record.url?scp=0038238640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038238640&partnerID=8YFLogxK

M3 - Article

C2 - 12828103

AN - SCOPUS:0038238640

VL - 50

SP - 851

EP - 855

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 51

ER -